PD718 - BASELINE TOTAL CHOLESTEROL (TCHOL) LEVELS AS SURROGATE MARKER OF MALNUTRITION IN PATIENTS (PTS) WITH ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) STARTING FIRST-LINE CHEMOTHERAPY
PD718
BASELINE TOTAL CHOLESTEROL (TCHOL) LEVELS AS SURROGATE MARKER OF MALNUTRITION IN PATIENTS (PTS) WITH ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) STARTING FIRST-LINE CHEMOTHERAPY
L. Goscilo1,*, M. R. Lupattelli1, L. Toti1, G. Del Vecchio Blanco 1, E. De Cristofaro 1, E. Troncone1, G. Del Pace1, S. Riondino 1, G. Torquati1, R. Argirò1, T. Cenci 1, M. C. Rapanotti 1, C. Morelli1, M. Rofei 1, M. Roselli1, V. Formica1
1University of Rome Tor Vergata, Rome, Italy
Rationale: Pts with PDAC starting first-line chemotherapy are at high risk of malnutrition, associated with poor prognosis. This observational study aims to identify biochemical surrogate markers of malnutrition to support clinical management in this setting.
Methods: Pts with advanced PDAC starting standard first-line gemcitabine-based chemotherapy were enrolled and assessed before treatment using the Patient-Generated Subjective Global Assessment-Short Form (PG-SGA SF) and the following key biochemical parameters: hemoglobin, white blood cells, albumin, total lymphocyte count, ferritin, C-reactive protein, Tchol, blood glucose, vitamin D, CA 19-9. Malnutrition was defined as a PG-SGA SF ≥9. Basic demographic and clinical data were also collected. The ROC curve analysis, chi-square and odds ratio tests were used to investigate the association between biochemical parameters with malnutrition.
Results: Fifty-four pts were enrolled (median age 64 years; range 39-81; 34% women, 66% men). Overall, 46.3% were malnourished. There is no significant difference in median BMI between malnourished and non-malnourished groups (22.8 vs 22.4; Mann-Whitney p=0.7417). Tchol showed a significant ability to discriminate between malnourished and non-malnourished pts, (AUC 0.657 95% CI 0.516-0.781, p=0.04). Pts with Tchol of >160 mg/dL had a 64% risk of being malnourished compared to 27% of pts with Tchol ≤160 (p=0.006); corresponding to a 4.9 times higher odds of malnutrition (OR=4.8857; 95% CI 1.5296-15.6051; p=0.0074).
Conclusion: Our preliminary results suggest that elevetion of Tchol may represent a compensotary mechanisms of malnutrition in pts with advanced PDAC starting a first-line chemotherapy and could be used as a surrogate marker for future nutritional trials.
Disclosure of Interest: None declared